HK1216302A1 - 抗毒蕈鹼化合物的粒度減小 - Google Patents

抗毒蕈鹼化合物的粒度減小

Info

Publication number
HK1216302A1
HK1216302A1 HK16104300.9A HK16104300A HK1216302A1 HK 1216302 A1 HK1216302 A1 HK 1216302A1 HK 16104300 A HK16104300 A HK 16104300A HK 1216302 A1 HK1216302 A1 HK 1216302A1
Authority
HK
Hong Kong
Prior art keywords
particle size
size reduction
antimuscarinic compound
antimuscarinic
compound
Prior art date
Application number
HK16104300.9A
Other languages
English (en)
Inventor
‧帕斯瓜利
‧卡薩薩
‧桑德斯
‧洛斯
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of HK1216302A1 publication Critical patent/HK1216302A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16104300.9A 2013-04-26 2016-06-08 抗毒蕈鹼化合物的粒度減小 HK1216302A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165483 2013-04-26
PCT/EP2014/058295 WO2014173987A1 (en) 2013-04-26 2014-04-24 Particle size reduction of an antimuscarinic compound

Publications (1)

Publication Number Publication Date
HK1216302A1 true HK1216302A1 (zh) 2016-11-04

Family

ID=48190260

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104300.9A HK1216302A1 (zh) 2013-04-26 2016-06-08 抗毒蕈鹼化合物的粒度減小

Country Status (28)

Country Link
US (2) US9393202B2 (zh)
EP (2) EP3574895B1 (zh)
JP (1) JP6449246B2 (zh)
KR (1) KR102198354B1 (zh)
CN (1) CN105120841B (zh)
AR (1) AR096087A1 (zh)
AU (1) AU2014259443B2 (zh)
BR (1) BR112015024626B1 (zh)
CA (1) CA2910314C (zh)
DK (2) DK2988728T3 (zh)
ES (2) ES2943109T3 (zh)
FI (1) FI3574895T3 (zh)
HK (1) HK1216302A1 (zh)
HR (2) HRP20230337T1 (zh)
HU (2) HUE062002T2 (zh)
IL (1) IL242209A (zh)
MX (1) MX365295B (zh)
MY (1) MY169127A (zh)
PH (1) PH12015502449A1 (zh)
PL (2) PL2988728T3 (zh)
PT (2) PT2988728T (zh)
RU (1) RU2667636C2 (zh)
SG (1) SG11201508760VA (zh)
SI (2) SI3574895T1 (zh)
TW (1) TWI630926B (zh)
UA (1) UA120418C2 (zh)
WO (1) WO2014173987A1 (zh)
ZA (1) ZA201507916B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015004243A1 (en) 2013-07-11 2015-01-15 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
CN107106515A (zh) 2014-10-16 2017-08-29 梯瓦优质制药产品研发股份有限公司 可吸入的配制剂
JP6500522B2 (ja) * 2015-03-16 2019-04-17 セイコーエプソン株式会社 回路装置、物理量検出装置、電子機器及び移動体
PT3377109T (pt) 2015-11-16 2020-05-13 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico
PT3620176T (pt) 2015-11-16 2021-09-28 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
EP3490533B1 (en) * 2016-07-29 2020-05-27 Inke, S.A. Particle size stabilization process

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2118517C (en) * 1992-06-10 2003-10-14 Gary G. Liversidge Surface modified nsaid nanoparticles
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
KR20050085035A (ko) * 2002-11-18 2005-08-29 이 아이 듀폰 디 네모아 앤드 캄파니 비구형 분쇄 매체를 사용하는 매체 밀링
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0516549D0 (en) 2005-08-12 2005-09-21 Sulaiman Brian Milling system
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2229148B1 (en) * 2007-12-13 2014-03-05 Novartis AG Process for preparing a particulate and crystalline drug substance
KR20100099281A (ko) * 2007-12-13 2010-09-10 노파르티스 아게 유기 화합물
DE102008000482A1 (de) 2008-03-03 2009-09-10 Zf Friedrichshafen Ag Ölgekühltes Reibschaltelement
EP2321023B1 (en) * 2008-07-18 2016-06-15 Prosonix Limited Process for improving crystallinity of fluticasone particles
EP2435024B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
JP2014504260A (ja) * 2010-10-15 2014-02-20 グラクソ グループ リミテッド 集合ナノ粒子状薬物製剤、その製造及び使用
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound

Also Published As

Publication number Publication date
UA120418C2 (uk) 2019-12-10
ES2943109T3 (es) 2023-06-09
JP2016521274A (ja) 2016-07-21
PT3574895T (pt) 2023-04-28
TW201521790A (zh) 2015-06-16
HRP20191882T1 (hr) 2019-12-27
SI2988728T1 (sl) 2019-11-29
IL242209A (en) 2017-12-31
AU2014259443A1 (en) 2015-11-12
CN105120841A (zh) 2015-12-02
PT2988728T (pt) 2019-11-18
HUE046213T2 (hu) 2020-02-28
MY169127A (en) 2019-02-18
HUE062002T2 (hu) 2023-09-28
DK2988728T3 (da) 2019-11-04
MX365295B (es) 2019-05-29
RU2667636C2 (ru) 2018-09-21
CA2910314A1 (en) 2014-10-30
US9393202B2 (en) 2016-07-19
TWI630926B (zh) 2018-08-01
FI3574895T3 (fi) 2023-05-25
AU2014259443B2 (en) 2019-01-03
PL3574895T3 (pl) 2023-06-19
KR20160002733A (ko) 2016-01-08
US9889094B2 (en) 2018-02-13
DK3574895T3 (da) 2023-05-01
EP2988728A1 (en) 2016-03-02
EP2988728B1 (en) 2019-08-21
WO2014173987A1 (en) 2014-10-30
PH12015502449B1 (en) 2016-02-22
ES2754255T3 (es) 2020-04-16
HRP20230337T1 (hr) 2023-06-09
US20140322142A1 (en) 2014-10-30
CN105120841B (zh) 2019-04-30
BR112015024626A2 (pt) 2017-07-18
AR096087A1 (es) 2015-12-02
ZA201507916B (en) 2017-05-31
JP6449246B2 (ja) 2019-01-09
PL2988728T3 (pl) 2020-02-28
KR102198354B1 (ko) 2021-01-06
PH12015502449A1 (en) 2016-02-22
BR112015024626B1 (pt) 2022-11-01
MX2015014904A (es) 2016-03-07
RU2015145521A (ru) 2017-05-16
SG11201508760VA (en) 2015-11-27
SI3574895T1 (sl) 2023-05-31
US20160279066A1 (en) 2016-09-29
EP3574895B1 (en) 2023-03-22
EP3574895A1 (en) 2019-12-04
CA2910314C (en) 2022-03-01

Similar Documents

Publication Publication Date Title
IL276456B (en) Tetrahydroquinoline preparations as bromodomain bet inhibitors
IL249517A0 (en) A compound that inhibits trk
HK1216302A1 (zh) 抗毒蕈鹼化合物的粒度減小
GB201302368D0 (en) Compound
HK1219100A1 (zh) 吡啶基吡唑並喹啉化合物
GB201307295D0 (en) Brake shield
IL241070A0 (en) Powder particles with additional coating
EP2947066A4 (en) PHENOXYALKYLAMINVERBINDUNG
EP3010982A4 (en) ENCAPSULATION OF SOLID PARTICLES
GB201307331D0 (en) Compound
HK1208689A1 (zh) 粒度降低方法
GB201408643D0 (en) Compound
GB2513424B (en) Apparatus for reducing particle size
PL2948131T3 (pl) Formowanie struktur cząstkowych
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound